Drug Profile


Alternative Names: BAM-205; Molixan; NOV-205

Latest Information Update: 02 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BAM
  • Developer BAM; Cellectar Biosciences
  • Class Antivirals; Hepatoprotectants; Peptides; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Suspended Radiation injuries

Most Recent Events

  • 11 Feb 2014 Novelos Therapeutics is now called Cellectar Biosciences
  • 18 Jan 2011 Novelos Therapeutics completes a phase II trial in Hepatitis C in the US
  • 12 Oct 2010 Novelos Therapeutics completes enrolment in its phase II trial (NCT01058512) for hepatitis C in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top